At Aurinia Pharmaceuticals, we’re developing innovative products for patients living with debilitating diseases.
Voclosporin has the potential to be the first therapy approved for the treatment of lupus nephritis (LN) in the United States and Europe.
Aurinia is a global clinical stage biopharmaceutical company focused on developing and commercializing innovative products to treat serious diseases.
Our leadership team has more than 100 years of combined industry specific experience in both small and large organizations.
November 9, 2018 • 12:00am EST
November 8, 2018 • 12:00am EST
October 25, 2018 • 12:00am EDT
